Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: A bilineal clonal malignancy

European Journal of Haematology

Volumn 80, Issue 1, 2008, Pages 81-86

  Capovilla, Mathieu ^a,b   Cayuela, Jean Michel ^c   Bilhou Nabera, Chrystèle ^d   Gardin, Claude ^b   Letestu, Remi ^a   Baran Marzak, Fanny ^a   Fenaux, Pierre ^b   Martin, Antoine ^b  

^a AVICENNE HOSPITAL   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d BICÊTRE HOSPITAL   (France)

Author keywords

CHIC2 deletion; Chronic eosinophilic leukemia; FIP1L1 PDGFRA rearrangement; Hypereosinophilia; T cell lymphoblastic lymphoma

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR A;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CELL DIFFERENTIATION; CELL PROLIFERATION; EOSINOPHILIC LEUKEMIA; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LYMPHOBLASTOMA; MALE; MAST CELL; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; T CELL LYMPHOMA; T LYMPHOCYTE;

ADULT; CELL LINEAGE; CLONE CELLS; HUMANS; HYPEREOSINOPHILIC SYNDROME; LYMPHOMA, T-CELL; MALE; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; ONCOGENE PROTEINS, FUSION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RNA, MESSENGER;

EID: 37249033190     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2007.00973.x     Document Type: Article

References (20)

1. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003 348 : 1201 14.
2. Robyn J, Lemery S, McCoy JP, Kubofcik J, Kim Y, Pack S, Nutman TB, Dunbar C, Klion AD. Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Br J Haematol 2006 132 : 286 92.
3. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003 102 : 3093 6.
4. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, Metcalfe DD, Dunbar C, Nutman TB. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patient with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004 103 : 473 8.
5. Metzgeroth G, Walz C, Score J, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007 21 : 1183 8.
6. Cools J, Quentmeier H, Huntly BJP, Marynen P, Griffin JD, Drexler HG, Gilliland DG. The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2004 103 : 2802 5.
7. Bain B, Pierre R, Imbert M. Chronic eosinophilic leukemia and the hypereosinophilic syndrome. In : Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARC Press, 2001 : 29 31.
8. Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed 2001 3 : 9.
9. Kaufmann I, Martin G, Friedlein A, Langen H Keller W. Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly (A) polymerase. EMBO J 2004 23 : 616 26.
10. Vandenberghe P, Wlodarska I, Michaux L, et al. Clinical and molecular features of FIP1L1-PDGFRA (+) chronic eosinophilic leukemias. Leukemia 2004 18 : 734 42.
11. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004 104 : 3038 45.
12. Tefferi A, Lasho TL, Brockman SR, Elliott MA, Dispenzieri A, Pardanani A. FIP1L1-PDGFRA and c-KIT D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia. Haematologica 2004 89 : 871 3.
13. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004 77 : 82 5.
14. Lemery SJ, Robyn JA, McCoy JP, Kubofcik J, Kim Y, Nutman TB, Dunbar CE, Klion AD. Lineage analysis of the FIP1L1-PDGFRα fusion gene in myeloproliferative hypereosinophilic syndrome (abstract). Blood 2004 104 : 670a 1a.
15. Abruzzo LV, Jaffe ES, Cotelingam JD, Whang-Peng J, Del Duca V, Medeiros LJ. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol 1992 16 : 236 45.
16. Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R, Stone RM. A syndrome of lymphoblastic lymphoma, eosinophilia and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 1995 85 : 81 7.
17. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002 107 : 101 7.
18. Buitenhuis M, Verhagen LP, Cools J, Coffer PJ. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 2007 67 : 3759 66.
19. Gotlib J. Molecular classification and pathogenesis of eosinophilic disorders: 2005 update. Acta Haematol 2005 114 : 7 25.
20. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland G, Coutré SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification and management. Blood 2004 103 : 2879 91.